The Corneal Dystrophy drugs in development market research report provides comprehensive information on the therapeutics under development for Corneal Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Corneal Dystrophy. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Corneal Dystrophy and features dormant and discontinued products.
GlobalData tracks 25 drugs in development for Corneal Dystrophy by 24 companies/universities/institutes. The top development phase for Corneal Dystrophy is preclinical with nine drugs in that stage. The Corneal Dystrophy pipeline has 21 drugs in development by companies and four by universities/ institutes. Some of the companies in the Corneal Dystrophy pipeline products market are: ActualEyes, Medicibio and Arctic Vision Shanghai Biotechnology.
The key targets in the Corneal Dystrophy pipeline products market include Rho Kinase (Rho Associated Coiled Coil Forming Protein Kinase or ROCK or EC 2.7.11.1), Transforming Growth Factor Beta 1 (TGFB1), and Keratin Type I Cytoskeletal 12 (Cytokeratin 12 or Keratin 12 or KRT12).
The key mechanisms of action in the Corneal Dystrophy pipeline product include Rho Kinase (Rho Associated Coiled Coil Forming Protein Kinase or ROCK or EC 2.7.11.1) Inhibitor with three drugs in Phase III. The Corneal Dystrophy pipeline products include seven routes of administration with the top ROA being Ophthalmic and ten key molecule types in the Corneal Dystrophy pipeline products market including Small Molecule, and Gene Therapy.
Corneal Dystrophy overview
Corneal dystrophy (CD) is defined as a collection of rare hereditary non-inflammatory disorders of abnormal deposition of substances in the cornea. The material may cause the cornea to lose its transparency and can cause loss of vision or blurred vision. Corneal dystrophies can appear at any age and men and women are equally affected by most corneal dystrophies. The symptoms of corneal dystrophy depend upon the type of corneal dystrophy. Some people experience no symptoms. In others, the build-up of material in the cornea causes it to become opaque (not clear). This leads to blurred vision or vision loss
For a complete picture of Corneal Dystrophy’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
